Key clinical point: In patients with multiple sclerosis (MS), protein concentrations of inflammatory cytokines, interleukin (IL)-27, transforming growth factor beta-1 (TGF-β1), and IL-10 are upregulated after 8 weeks of vitamin D 3 supplementation.
Major finding: In patients with MS, 8 weeks of vitamin D 3 administration upregulated the levels of IL-27 ( P = .001), TGF-β1 ( P less than .001), and IL-10 ( P less than .001), whereas levels of IL-17A ( P = .024) and IL-6 ( P less than .001) were downregulated.
Study details: The study assessed venous blood samples drawn from individuals with MS (n=25) and control participants including first-degree relative (n=25) and healthy participants (n=25) before and after vitamin D 3 supplementation of 50,000 IU.
Disclosures: Dr SR Arefhosseini received financial support from Nutrition Research Center and Tabriz University of Medical Sciences, Tabriz, Iran.
Citation: Hashemi R et al. PLoS One. 2020 Apr 6. doi: 10.1371/journal.pone.0231145.